<ARTICLE> 5 <LEGEND> THE FINANCIAL DATA SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM HOUSTON BIOTECHNOLOGY INCORPORATED 10Q DATED 9-30-96AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <PERIOD-TYPE> 9-MOS <FISCAL-YEAR-END> DEC-31-1996 <PERIOD-END> SEP-30-1996 <CASH> 163,674 <SECURITIES> 0 <RECEIVABLES> 0 <ALLOWANCES> 0 <INVENTORY> 0 <CURRENT-ASSETS> 220,493 <PP&E> 2,622,777 <DEPRECIATION> 2,298,632 <TOTAL-ASSETS> 556,751 <CURRENT-LIABILITIES> 1,108,773 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 56,387 <OTHER-SE> (818,698) <TOTAL-LIABILITY-AND-EQUITY> 556,751 <SALES> 925,000 <TOTAL-REVENUES> 1,009,541 <CGS> 0 <TOTAL-COSTS> 1,642,734 <OTHER-EXPENSES> 0 <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 0 <INCOME-PRETAX> (633,193) <INCOME-TAX> 0 <INCOME-CONTINUING> (633,193) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (633,193) <EPS-PRIMARY> (.11) <EPS-DILUTED> (.11)